Value of α‑fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma by Plano Sánchez, Ana Isabel et al.
ONCOLOGY LETTERS  15:  8863-8870,  2018
Abstract. Sorafenib is an oral multikinase inhibitor with 
antiangiogenic and antiproliferative properties, and is used 
as the first‑line treatment for patients with advanced hepato-
cellular carcinoma (HCC). Previous studies have identified 
an improvement in overall survival and progression-free 
survival in patients with a manageable toxicity profile. 
α-fetoprotein (AFP) has been revealed to be of great diag-
nostic and predictive value for tumour staging in multiple 
studies; however, its role as a predictive factor of response 
to treatment with sorafenib is not entirely clear. The present 
study aimed to determine the effectiveness of sorafenib and 
investigate the value of AFP as a predictive factor of early 
response to sorafenib in patients with HCC. Effectiveness 
was analysed based on median overall survival (mOS) 
time, while to analyse the possible predictive value of AFP, 
patients were classified into two groups: Non-responders 
(≤20% AFP reduction) and responders (>20% AFP reduc-
tion) at 6-8 weeks of treatment when compared with basal 
AFP level. For assessment of toxicity, any adverse effects 
were recorded. A total of 167 patients were included, who 
collectively exhibited a mOS time of 11 months with a 
median treatment duration of 5 months. The mOS time was 
significantly higher for patients with better hepatic function 
(12 months in cases of Child-Pugh score A vs. 8 months in 
cases of Child-Pugh score B; P=0.03) and with basal AFP 
values ≤200 ng/ml (14 months vs. 8 months in patients with 
AFP levels >200 ng/ml; P=0.01). A >20% reduction of AFP 
at 6-8 weeks was determined to be a positive predictive 
factor upon multivariate analysis (P=0.002), obtaining, for 
the responder patients, an mOS of 18 months compared 
with 10 months (P=0.004) for the non‑responders. The main 
adverse reactions were hand‑foot syndrome (35/167; 21%), 
diarrhoea (39/167; 23.4%), anorexia (29/167; 17.4%) and arte-
rial hypertension (30/167; 18%). In conclusion, a >20% drop 
in AFP at 6-8 weeks may be useful as a predictive factor 
of response to sorafenib, as indicated by its association 
with longer survival times in patients with advanced HCC 
following treatment with sorafenib in the present study.
Introduction
Hepatic cancer (HCC) is the sixth most common type of 
cancer, with ~782,000 new cancer cases in 2012 worldwide (1). 
In the majority of cases, HCC develops following cirrhosis 
of the liver, and is the primary cause of mortality in these 
patients (1,2)
The incidence of HCC has doubled in the last 20 years in 
the United States and Europe, and has exhibited the highest rate 
of increase among all cancer-associated causes of mortality in 
recent years (3). Approximately 90% of HCC cases are associ-
ated with known risk factors (4); the most frequent causes are 
chronic viral hepatitis [hepatitis C virus (HCV) and hepatitis B 
virus (HBV)], alcohol consumption, and exposure to aflatoxins 
(primarily in Africa and Asia), while other factors may also 
increase the risk, including obesity, tobacco use and fatty liver 
disease (5).
The most widely used technique in tumour staging is the 
Barcelona Clinic Liver Cancer (BCLC) system, as this is the 
only method that takes into account the spread of the tumour, 
hepatic function and the presence of symptoms, and thus has 
high predictive capacity (5). It establishes tumour prognosis 
in four stages, with each one having possible therapeutic 
indications. Patients with initial stage cancer (BCLC stage A) 
are candidates for potentially curative treatments, including 
surgical resection, percutaneous ablation and transplant, 
whereas those with intermediate stage (BCLC stage B) may 
be subject to palliative treatments, including arterial chemo-
embolization. In addition, sorafenib is used as a systematic 
treatment in the event of advanced HCC (BCLC stage C) (6).
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The prognosis of most solid tumours depends on the 
tumour stage; nevertheless, given that HCC is associated with 
hepatic cirrhosis in the majority of cases, and that the degree 
of hepatic function determines the therapeutic regimens and 
patient survival, assessing the level of hepatic dysfunction 
and tumour spreading is considered essential. Furthermore, 
the symptomatology has been shown to be of high predictive 
value, and is also indicative for selecting the most appropriate 
treatment.
With the current screening programmes performed, HCC 
is able to be diagnosed at earlier stages, thus making it possible 
to choose effective therapeutic methods. Surgical resection, 
transplant and percutaneous ablation achieve high complete 
response rates for tumours (7). Regarding palliative therapy, 
the only treatments to demonstrate an increase in survival 
rates have been chemoembolisation and sorafenib (8,9). 
Other therapies, including arterial embolisation without 
chemotherapy, external radiotherapy and radioembolisation 
have been demonstrated to exhibit antitumour activity, but 
have not demonstrated efficacy in terms of survival (10,11). 
Systematic chemotherapy with classic cytotoxic agents has 
not revealed any benefit for patient survival and is associated 
with high toxicity, and hormonal therapy, including the use 
of tamoxifen and octreotide, and antiandrogens, appears to 
be ineffective (7,9). Sorafenib is an oral multikinase inhibitor 
with antiproliferative and antiangiogenic activity, which has 
demonstrated efficacy in improving the overall survival of 
patients with advanced HCC. It is currently the only first‑line 
treatment indicated for advanced or intermediate-stage 
HCC following failure or contraindication of standard 
therapies (12).
In an international, multicentre, randomised and 
double‑blind study (SHARP) (13), sorafenib (400 mg/12 h) was 
evaluated compared with placebo treatment in patients with 
advanced HCC exhibiting conserved hepatic function (95% 
Child Pugh class A, 5% Child Pugh class B) and practically 
asymptomatic conditions [Eastern Cooperative Oncology 
Group Performance (ECOG) score 0-2]. This study revealed 
a significant improvement in overall survival, as well as in 
median time-to-radiological progression (mOS) of 10.7 vs. 
7.9 months in the placebo group.
A similarly designed clinical trial was performed in 
Asia (8), involving HCC cases at more advanced stages, 
with the large majority of cases involving tumours occur-
ring secondary to cirrhosis caused by the HBV. Sorafenib 
exhibited benefits similar to those described in the SHARP 
study, with a reduction in the risk of mortality, although it 
achieved a lower median survival time (6.5 vs. 4.2 months in 
the placebo group).
The monitoring of responses to treatments involves 
the monitoring of patients by performing imaging tests, 
including computed tomography or magnetic resonance 
imaging, and measuring α‑fetoprotein (AFP) levels. In 
order to define the stage of the illness prior to and following 
treatment, it is recommended that the Response Evaluation 
Criteria In Solid Tumors (RECIST) criteria are used (14,15). 
In general, clinical trials use imaging tests as a means of 
evaluating response to systematic treatments (14). However, 
numerous patients experience symptomatic improvement 
or evident improvement in pathology without exhibiting 
significant radiological changes (16). Numerous drugs exert 
cytostatic rather than cytotoxic activity, and inhibit the 
growth of tumours without causing a reduction in size (14). 
Furthermore, molecules, including sorafenib, induce tumour 
necrosis, which is occasionally associated with an increase 
in size or stabilisation of the tumour (14). The partial or 
complete response to treatment (assessed according to the 
RECIST criteria) is the primary independent predictive 
factor of survival in patients with HCC (14). Nonetheless, 
only in few cases is there a complete response to sorafenib, 
with a small proportion achieving a partial response (12). 
Furthermore, between 45 and 75% of patients exhibit stabili-
sation of the illness as their best response (15,16). Thus, it is 
important to perform studies that assess possible biomarkers 
or measures of response, to allow us to determine probable 
response predictors (17).
AFP is a serum glycoprotein that is elevated in over half of 
patients with HCC (14). A number of studies have demonstrated 
its value at the beginning of diagnosis as a predictive factor of 
survival (18). Indeed, serum AFP level is used for diagnosis, 
as a predictive marker and to evaluate response following 
systematic chemotherapy or radiological therapies (15). A 
previous study of 25 patients treated with systematic chemo-
therapy revealed that a reduction in AFP level of >50% was 
associated with a good clinical response to the treatment (19). 
Additionally, Chan et al (20) confirmed that a decline in basal 
AFP of >20% following 2‑3 cycles of systemic chemotherapy 
was predictive of response to treatment (20). However, only a 
small number of studies have been performed to investigate its 
role as a possible predictor of response following therapy with 
sorafenib in patients with HCC (21-23).
At present the use of sorafenib is indicated for patients 
with advanced HCC, for those who are not candidates for 
chemoembolization, or for those with post-chemoembolisation 
progression with conserved hepatic function (Child-Pugh 
class A).
The aim of the present study was to assess the effectiveness 
of sorafenib, and the value of AFP as a predictive factor of 
response, as well as other prognostic factors associated with 
overall survival, in patients diagnosed with advanced HCC 
treated with sorafenib as the first‑line treatment, or in patients 
with advanced-stage disease following progression or resis-
tance to standard treatment.
Materials and methods
Study design. The present study was an observational retro-
spective study of patients with HCC treated with sorafenib at 
the Central University Hospital of Asturias (Oviedo, Spain). 
The study was approved by the Ethical Research Committee 
of Central University Hospital of Asturias. Written informed 
consent was obtained for use of patient data, while maintaining 
patient anonymity and respecting patient confidentiality 
throughout.
Study population
Patients. Patients with HCC treated at the Central University 
Hospital of Asturias who started first-line treatment with 
sorafenib for advanced C stage, or as second-line treatment for 
intermediate stage B due to resistance to standard treatment 
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or progression, were enrolled. During the study period, 
167 patients began treatment with sorafenib with a median age 
of 65.6 years (range, 23.9‑80.6 years), and 147 (88%) men and 
20 (12%) women.
Inclusion criteria. All patients diagnosed with HCC who 
started treatment with sorafenib between January 2008 and 
December 2014 were included. The end date of the monitoring 
period was the 20th of December 2015.
Exclusion criteria. All those being treated with sorafenib 
during a clinical trial, along with those who had begun treat-
ment prior to 2008, when access to the drug was granted on 
request for compassionate use only were excluded. Those 
patients who lacked records for the variables studied on the 
computer systems used were also excluded, unless otherwise 
stated.
Treatments. All patients received 800 mg/day sorafenib 
(400 mg twice/day) as an initial dosage. Dosage reductions 
took place in accordance with the technical file upon signs of 
toxicity or adverse effects. The patients continued treatment 
unless there was clinical progression, unacceptable toxicity, or 
cases of patient refusal or patient mortality.
Variable definitions
Main variables. To assess the effectiveness of the treatment, the 
median overall survival (mOS) time, calculated as the interval 
(in days) between the beginning of treatment and the date of 
mortality, if mortality occurred, or the end date of monitoring 
for patients who survived (20th of December 2015) were used. 
To evaluate the possible predictive value of AFP in response to 
treatment, the patients were classified into two groups: Those 
with AFP reduction ≤20% (non‑responders) and those with 
AFP reduction >20% (responders), measured at 6‑8 weeks 
after starting treatment with sorafenib.
Secondary variables. To assess other possible factors predic-
tive of survival, the ECOG score (0, 1 or 2), aetiology, stage 
according to the BCLC system (BCLC stage B or C) and 
hepatic function based on the Child-Pugh classification 
(A or B) for each patient were determined. Additionally, 
whether or not at the beginning of the treatment the patient 
presented vascular invasion and/or extrahepatic extension 
was recorded. The analytical parameters recorded were basal 
serum levels of albumin (>35 or ≤35 g/l), basal serum AFP 
(>200 or ≤200 ng/dl) and serum AFP at 6‑8 weeks. Any other 
treatments administered prior to the beginning of sorafenib 
treatment were also recorded.
Toxicity. The adverse effects and the duration of the treatment 
were recorded. Any suspensions of treatment due to toxicity 
or an unknown factor, including low patient compliance, were 
also recorded.
Statistical analysis. A descriptive statistical analysis of the 
demographic and clinical variables was performed using 
centralisation and dispersion methods (median and inter-
quartile range) for the quantitative data, and frequencies and 
proportions for the qualitative data. Duration of the treatment 
was determined (in months), along with the time of appear-
ance of any adverse affects. In order to determine overall 
survival, Kaplan‑Meier curves were constructed and the 
differences between groups were analysed via the log-rank 
test. To identify the possible predictive factors associated with 
overall survival, the Cox proportional hazards model was used 
to determine respective hazard quotients and 95% confidence 
intervals (CIs). The variables identified as potential predictors 
of effectiveness in the univariate analysis were subsequently 
included in the multivariate analysis. For all of the analyses, 
P<0.05 was considered to indicate a statistically significant 
difference. Statistical analysis was performed using the SPSS 
statistical data package (version 19.0; IBM Corp., Armonk, 
NY, USA).
Results
Patient characteristics. All of the patients were diagnosed 
with advanced HCC; 82.3% of cases also presented with a 
cirrhosis of the liver and 61.7% exhibited advanced‑stage 
HCC (BCLC stage C). Alcohol consumption was the primary 
cause of HCC development (40.1%), followed by chronic 
HCV infection (21.6%). At the start of treatment, the majority 
of patients had preserved hepatic function, with Child-Pugh 
class A (42.5% patients). Clinical data regarding the spread 
of the disease was identified as incorrectly defined in certain 
registries, and therefore it was only possible to analyse a 
percentage of the total number of patients for this variable. Of 
the 117 patients for whom the presence or absence of extrahe-
patic extension was documented, this was positive in 46 cases 
(27.5% of the total). Information on vascular invasion was only 
assessable for 130 patients, with 80 cases (47.9% of the total) 
being positive for vascular invasion. Regarding basal AFP 
serum levels, 49 (29.3%) patients presented values >200 ng/ml. 
The demographical and clinical characteristics of patients are 
outlined in Table I.
Treatment. Prior to beginning treatment with sorafenib, 53 
(31.7%) patients had not received any treatment, 64 (38.3%) 
patients had received locoregional therapy [transarterial 
chemoembolization (TACE) and/or radiofrequency ablation], 
18 (10.8%) had undergone surgical resection with curative 
intent prior to sorafenib treatment and 7 (4.2%) had received 
liver transplants. No information was available on previous 
treatments for 25 patients.
The median duration of treatment was 5 months. During 
monitoring, 92 (55.1%) patients required a reduction in 
dosage. Progression of the illness was the primary reason 
for ending treatment in 94 (56.3%) patients (including those 
who succumbed while being treated), followed by adverse 
effects (41 patients, 24.6%). A total of 2 patients were moved 
on to trials with tivantinib, 2 (1.1%) with regorafenib, 1 with 
nivolumab (0.5%) and another to treatment with tamoxifen 
(0.5%), following the suspension of sorafenib.
Effectiveness and survival in different subgroups. On analysis 
of overall survival, an mOS time of 11 months was deter-
mined (95% CI, 8.65‑13.34). Two patients exhibited complete 
responses for 17 and 24 months, respectively, with both 
remaining alive until the date the monitoring ended.
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Statistical analyses of survival was performed between 
subgroups based on potential risk factors, including age, Child 
Pugh classification, BCLC stage, ECOG score, basal AFP 
>200 ng/ml and AFP reduction at 6‑8 weeks.
With regards to the basal AFP levels, notable differences 
in survival were observed, in that mOS time was significantly 
lower in those with initial AFP levels >200 ng/ml (mOS, 
8 months vs. 14 months in patients with AFP levels ≤200 ng/ml) 
(P=0.01; Fig. 1).
Another clinical variable that was associated with signifi-
cantly higher mOS was ECOG performance status, with an 
mOS of 16 months identified for patients with an ECOG of 0, 
compared with an mOS of 4 months in patients with an ECOG 
of 2 (P=0.001). Hepatic function was also an influential factor, 
with Child‑Pugh class A associated with a significantly higher 
mOS of 12 months, compared with 8 months for Child-Pugh 
class B (P=0.03; Fig. 2). Lastly, those patients aged >63 years 
exhibited a higher mOS time (14 months vs. 8 months in 
patients ≤63 years old; P=0.03). Patients at BCLC stage B 
exhibited increased mOS times compared with patients at 
BCLC stage C (15 vs. 10 months), without reaching statistical 
significance.
Role of AFP reduction as a predictive factor of early response. 
Of the 167 patients, 28 belonged to the AFP responders group, 
whereas 139 belonged to the non-responder group. The AFP 
responder patients exhibited a difference in mOS compared 
with the non‑responders (18 vs. 10 months; Fig. 3; P=0.004).
A multivariate analysis was performed to assess the 
potency of the AFP variable as an independent predictive 
factor, as well as the value of the other clinical variables that 
were significant in the univariate analysis (Table II). A reduc-
tion in AFP by >20% at 6‑8 weeks was an independent factor 
associated with higher mOS time (P=0.002).
Basal AFP levels of ≤200 ng/ml and age >63 years were 
also identified as independent factors associated with higher 
mOS time.
Toxicity. With regards to the toxicity of treatment, the 
primary adverse reactions registered in the medical records 
were hand‑foot syndrome (35 patients, 21%), diarrhoea 
(39 patients, 23.4%), anorexia (29 patients, 17.4%) and 
arterial hypertension (30 patients, 18%). Seven cases of 
encephalopathy were registered (4.2%), 1 patient suffered 
an ischaemic stroke (0.6%), 2 exhibited angina with atrial 
fibrillation (1.2%), 1 exhibited myocardial infarction (0.6%) 
and treatment was suspended for 2 patients (1.2%) due to 
intense haemorrhoid bleeding.
Discussion
A number of studies have demonstrated that sorafenib is 
effective in the treatment of HCC, particularly by increasing 
the overall survival times compared with placebos, while 
having a manageable toxicity profile (13,24,25). Thus, it 
has become established as a first‑line treatment for patients 
with advanced HCC. In clinical practice, serum AFP is used 
as a biomarker in HCC. There are studies that support the 
efficacy of AFP level as a predictive factor and as a response 
factor following surgical resection (16,26); nonetheless, its 
Table I. Baseline demographical and clinical characteristics of 
patients.
Variable Value
Total patients, n 167
Age, years [median (range)] 65.6
 (23.9-80.6)
Sex, n (%) 
  Male 147 (88)
  Female 20 (12)
Child‑Pugh class, n (%) 
  A 71 (42.5)
  B 17 (10.4)
ECOG performance status, n (%) 
  0 71 (42.5)
  1 29 (17.4)
  2 4 (2.4)
Aetiology of HCC, n (%) 
  VHB cirrhosis 5 (3)
  VHC cirrhosis 36 (21.6)
  VHC cirrhosis and alcohol 17 (10.2)
  VHB cirrhosis and alcohol 4 (2.4)
  Alcoholic cirrhosis 67 (40.1)
  Hepatitis C+HIV 5 (3)
  Hemochromatosis 5 (3)
  HCV+HBV 1 (0.6)
  Other 27 (16.1)
BCLC stage, n (%) 
  B 38 (22.8)
  C 103 (61.7)
Vascular invasion, n (%) 80 (47.9)
  Extrahepatic extension 46 (27.5)
  Liver transplant 7 (4.2)
Basal AFP level, ng/ml [median (range)] 76.6
 (1.2-233800.0)
Basal AFP >200 ng/ml, n (%) 49 (29.3)
Basal AFP ≤200 ng/ml, n (%) 118 (70.7)
Basal hepatic enzymes, IU/l [median (range)]
  Aspartate aminotransferase 58 (19‑344)
  Alanine aminotransferase 44.5 (13‑274)
Basal albumin value, g/l [median (range)] 39 (25‑48)
Basal albumin ≤35 g/l, n (%) 63 (37.7)
Basal albumin >35 g/l, n (%) 104 (62.3)
Basal bilirubin value, mg/ml [median (range)] 1 (0.2‑4.4)
Basal bilirubin ≤1 mg/ml, n (%) 80 (47.9)
Basal bilirubin >1 mg/ml, n (%) 87 (52.1)
AFP reduction at 6‑8 weeks, n (%) 
  AFP responders (>20%) 28 (16.8)
  AFP non‑responders (≤20%) 139 (86.2)
Certain data were not available for all patients. AFP, α-fetoprotein; 
BCLC, Barcelona Clinic Liver Disease; ECOG, Eastern Cooperative 
Oncology Group Performance; HCV, hepatitis C virus; HBV, hepa-
titis B virus; HIV, human immunodeficiency virus.
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usefulness as a predictive factor of response to treatment 
with sorafenib or other anti-angiogenics drugs is not clearly 
established.
The results regarding the overall survival and toxicity 
profile associated with sorafenib in the present study are 
similar to those reported in the SHARP trial (13). This may 
be due to similarities in the demographical and clinical char-
acteristics collected from the patients in the present study 
and those in the SHARP study (13), which reported a higher 
incidence in males (88%) and in those aged ~65 years (median, 
65.6 years), involving patients in a good general state (92%, 
ECOG score 0‑1) and with advanced‑stage HCC (73%).
Regarding prior treatments, nearly half of the patients 
(71/167, 42.5%) in the current study had been treated with 
other optional palliative therapies, with a predominance 
of TACE at a similar frequency to that in the SHARP 
trial, with the only difference being that no patient in the 
present study had previously received hormone therapy or 
systematic chemotherapy. A sub-analysis of the SHARP trial 
performed by Bruix et al (24) identified a tendency towards 
improvement in overall survival in patients who received 
prior therapies independently of the treatment received, 
with an mOS time of 8.8 months for those treated with cura-
tive therapy and 9.9 months for those who received other 
palliative treatments. Indeed, in the current study cohort, a 
difference in mOS time (24) between patients treated with 
curative therapy (25 months) and those who had received 
other palliative treatments was observed (11 months; 95% CI, 
8.3‑41.6 and 7.8‑14.1, respectively).
The present study cohort exhibited an overall mOS time 
(11 months) similar to the SHARP trial (10.7 months) and 
slightly lower compared with that in the study by Kudo et al (26) 
(13.7 months). However, it was higher compared with that in an 
extended population of the SHARP study involving an Asian 
population (6.5 months), (8) as well as in other subsequent 
studies performed (5.4 months) (27). Previous data exhibit a 
tendency towards improvement in survival for those patients 
with good liver function and general state (ECOG perfor-
mance status) (28-30). Regarding the parameters analysed, 
high levels of basal AFP were an indicator of poor prognosis 
in the present study, and have previously been associated with 
shorter survival times (27,31). A sub-analysis of the SHARP 
trial performed by Raoul et al (32) analysed the influence 
of laboratory parameters, including hepatic enzymes, AFP 
and bilirubin, on the response to treatment with sorafenib. 
Figure 1. Kaplan‑Meier Curve of overall survival in the >200 and ≤200 ng/ml 
basal AFP risk subgroups. AFP, α-fetoprotein.
Figure 2. Kaplan‑Meier Curve of overall survival in the Child‑Pugh class A 
and B risk subgroups.
Figure 3. Kaplan‑Meier Curve of overall survival based on AFP reduction 
in the non‑responder (≤20% AFP reduction) and responder (>20% AFP 
reduction) risk subgroups. AFP, α-fetoprotein.
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Patients who demonstrated elevated levels of these markers 
had OS rate shorter (although the sorafenib cohort had greater 
OS rate, compared with the placebo group), compared with 
patients whose markers were normalised in both cohorts (32). 
Thus, the authors concluded that these markers had predic-
tive value in HCC, but were not predictive of response to 
treatment with sorafenib in the HCC patients. In the present 
study, when analysing mOS time according to subgroups, the 
patients who presented AFP values of >200 ng/ml exhibited 
a significantly lower mOS time, compared with the AFP 
≤200 ng/ml group. Another study performed on a Korean 
population by Lee et al (33) revealed that liver function 
(Child-Pugh class A) and low basal AFP levels were indepen-
dent risk factors associated with longer mOS times (P=0.02 
and P=0.03, respectively) (33). In the current group of patients, 
AFP levels >200 ng/ml was identified as an independent 
predictor of shorter survival time in the multivariate analysis; 
nevertheless, good liver function (Child-Pugh class A), 
despite indicating improved survival (12 vs. 8 months in cases 
of Child Pugh class B) in the subgroup analysis (P>0.05), was 
not deemed to be statistically significant as an independent 
predictive factor on performance of the multivariate test.
A number of studies performed with different systemic 
chemotherapy treatments determined that a drop in AFP level 
may be useful as a predictive marker for tumour response and 
overall survival (17,20,34), although no consensus was achieved 
regarding the amount of reduction and the measurement times. 
Personeni et al (21) classified those patients with a reduction in 
AFP levels of ≥20% at 6‑8 weeks as responders, and those with 
an AFP of ≤20% as non‑responders. Another study restricted 
the definition of responder to a drop in AFP of >50%, thus 
increasing the potency and specificity of AFP as a predictor 
of response treatment (35). A reduction in AFP measured at 
6-8 weeks is considered relevant and applicable in clinical 
practice for aggressive pathologies, including HCC, with short 
mOS times of 4‑6 months, with treatments that achieve this 
also having a beneficial impact on medical costs (8,27). This 
study demonstrated that an early drop in AFP level (>20%) 
by 6-8 weeks of treatment with sorafenib is associated with 
improved patient survival, with higher greater mOS time 
observed for the AFP responder group (18 vs. 10 months in the 
non‑responder group, log rank P=0.004), which is in accor-
dance with other previous studies (22,36), despite a number of 
these not reaching statistical relevance (28,37).
In addition, a >20% reduction in AFP was a significant 
independent predictive factor of response to treatment in 
the univariate analysis and subsequent multivariate analysis. 
Thus, >20% AFP reduction was useful as a predictive marker 
of early response to sorafenib in patients with HCC, being 
associated with a higher survival rate. This quickly detect-
able biomarker requiring inexpensive methods may predict 
whether treatment is effective, and ultimately identify 
patients who may benefit from a continuation of treatment 
from those who should be referred for alternative therapies.
Although high levels of AFP are associated with negative 
prognoses, the value of AFP as an early response marker 
to sorafenib in patients with HCC is not entirely clear. It is 
necessary to perform prospective studies specifically designed 
to assess the potency of AFP reduction in predicting patient 
prognosis to validate the preliminary results of the present 
study. Additionally, the current study included a number of 
limitations, primarily deriving from its retrospective design: 
Data were not available for all variables for the 167 patients, 
and were included as missing in the statistical analysis, which 
thus resulted in a loss of potency.
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